TrialJournal of patient-reported outcomes2025

Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial.

Manuel De la Torre-Aláez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.